Loading...
Loading...
According to Bank of America, Optimer Pharmaceuticals
OPTR Buy rating is reiterated.
Bank of America said that Optimer recorded $13.3mn in end market sales for its antibiotic Dificid in 4Q11, a healthy uptick from $6.9mn in 3Q11. “We expect meaningful royalty payments to Cubist in the next 2 years, as we expect the co-marketing alliance to successfully exceed sales targets.”
Optimer Pharmaceuticals closed yesterday at $12.13.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in